Skip to content

Kidney Perfusion With or Without Absorption

A Single-center, Pilot, Prospective, Randomized Clinical Study of Hypothermic Oxygenated Perfusion With or Without Adsorption in Histologically Evaluated Kidneys Retrieved From Marginal Donors

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06374121
Acronym
POWER
Enrollment
10
Registered
2024-04-18
Start date
2024-10-22
Completion date
2026-05-31
Last updated
2024-11-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Replacement

Keywords

Kidney perfusion, Absorption, Marginal donors

Brief summary

In this single-center, pilot, prospective, randomized study, the investigators will compare the biochemical profiles of the perfusate and the functional parameters of five kidneys perfused with Integrated PerLife® system and PerSorb ECOS-300CY ™ sorbent (adsorption groups) with the profiles of the perfusate and functional parameters of five matched kidneys perfused with Integrated PerLife® system only (non-adsorption group). Kidneys from marginal donors with a clinical indication to pre-transplant histological evaluation (donor \>70-years-old or aged 60 to 69 years but with hypertension, diabetes and/or clinical proteinuria) will be allocated to perfusion with or without adsorption using a 1:1 randomization ratio. When both donor kidneys will have a score from 0 to 4, the two kidneys will be used for two single transplants. When one kidney will have a score from 0 to 4 and the other kidney will have a score of 5 or more, and when both kidneys will have a score from 5 to 7, the two kidneys will be transplanted together into the same recipient. If one kidney will have a score from 5 to 7 and the other kidney will have a score of 8 or greater, the two kidneys will be discarded. With the use of the minimization method, the randomization will be planned in order to have the same number of single or dual transplants in the perfusion kidney groups with or without adsorption. Donor selection, kidney evaluation and allocation and recipient management will be based on per center practice.

Detailed description

In recent years, growing interest has been addressed to the use of dynamic preservation of the kidneys as a tool to improve graft function and survival. Retrospective analyses and a randomized controlled trial showed that pre-transplant machine perfusion (MP) is associated with a lower incidence of delayed graft function (DGF) and improved one-year graft survival as compared with static cold storage. However, the overall beneficial effect of MP on transplant outcomes is largely driven by treatment effect in recipients of grafts from marginal donors. Hypothermic oxygenated perfusion has been found to reduce early allograft injury and to improve post-transplant outcomes in a randomized controlled trial of liver transplantation from older donors. In vitro studies show that perfusion reduces endothelial damage to the sinusoidal capillaries and increases adenosine triphosphate production. As far as kidney transplantation is concerned, little data is available on the outcomes of grafts treated with perfusion. In rat models of allogeneic kidney transplant, perfusion-treated grafts displayed better short-term function, less tubular injury, fewer interstitial infiltrates of immune cells and milder endothelial activation than the untreated counterparts. MP is not only beneficial per se. It can also be exploited as a means to deliver additional treatment to the graft. For instance, there is in vivo evidence that hemoadsorption improves renal blood flow during perfusion and reduces the release of cytokines and prostaglandins at reperfusion in a porcine model of kidney transplantation. Beneficial effects of hemoadsorption have been documented in the setting of continuous renal replacement treatment for septic shock. In the setting of pre-transplant organ conditioning, cytokine adsorption paired to normothermic perfusion has been found to reduce inflammatory gene expression and increase oxidative phosphorylation pathway gene expression in human kidneys. Whether adsorption paired to perfusion reduces the inflammatory response and whether this is of clinical relevance in transplantation of histologically evaluated kidneys from marginal donors, is worth investigating.

Interventions

DEVICEPerSorb cartridge (CytoSorbents Europe GmbH, Germany)

This is a highly bio-/hemo-compatible, low-flow resistance polymer cartridge able to remove cytokines and other inflammatory mediators via adsorption.

DEVICEPerLife PerKidney

The system for ex vivo kidney reconditioning (Aferetica, Italy), which allows hypothermic oxygenated pulsatile perfusion of the organ.

Sponsors

Mario Negri Institute for Pharmacological Research
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

To compare the biochemical profiles of the perfusate obtained from 5 kidneys treated with perfusion and concomitant adsorption, with that of the perfusate obtained from 5 kidneys treated with perfusion without adsorption.

Eligibility

Sex/Gender
ALL
Age
50 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males and females older than 50 years eligible for single or dual kidney transplant from marginal donors identified according to the NITp criteria (\>70-year-old or 60 to 70 years with hypertension and/or diabetes and/or clinical proteinuria) * Pre-transplant histological evaluation * Histological score ≤ 7 * Written informed consent.

Exclusion criteria

* Any factor that represents a contraindication to receive a deceased donor kidney transplant according to the NITp criteria, * Need for specific desensitization protocols because of a high immunological risk according to the NITp criteria, * Active enrollment in concomitant intervention studies, * Macroscopic vascular abnormalities that preclude the possibility of machine perfusion.

Design outcomes

Primary

MeasureTime frameDescription
Oxidative stress markersEvery 30 minutes during clinical perfusionGlutathione S-transferase (GST), lactate dehydrogenase (LDH) and free lactate
Acute kidney injury markersEvery 30 minutes during clinical perfusionNeutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1 (KIM-1) and endothelin
Inflammatory cytokine markersEvery 30 minutes during clinical perfusionInterleukin-6 (IL-6), interleukin-10 (IL-10) and tumor necrosis factor alpha (TNF-⍺)
Complement activation markersEvery 30 minutes during clinical perfusionComplement factor 3a (C3a), complement factor 5a (C5a) and soluble membrane attack complex (sC5bC9)
Vascular resistancesEvery 30 minutes during clinical perfusionRenal vascular resistances will be automatically collected through clinical perfuzione
Perfusate sample collectionAt clinical perfusion start, after 1 hour, then after 4 hours from start and every 2 hours thereafter, up to perfusion endPseudo-urine ureteral output will be separately assessed at sequential times during clinical perfusion

Countries

Italy

Contacts

Primary ContactCamillo Carrara, MD
pruggenenti@asst-pg23.it+3903545351
Backup ContactPiero L Ruggenenti, MD
pruggenenti@asst-pg23.it

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026